Two Products Sharing One Ingredient Are Not Dupes. They're Neighbours.

The shared-ingredient fallacy, in one sentence

The standard dupe comparison runs: this luxury-tier cream contains hyaluronic acid, and so does this drugstore-priced one, therefore they are the same product at a tenth of the cost. It is the reasoning of someone declaring two cars identical because both have engines.

Ingredient lists are not recipes. They tell you what is present, in a rough descending order that stops being ordered at all below one per cent, and they say nothing about concentration above that threshold, nothing about the grade or molecular weight of the material, nothing about pH, nothing about the emulsion structure holding it together, and nothing about what the manufacturing process did to any of it. Two formulas can share every INCI name and behave differently on skin. Two formulas can share almost none and behave identically.

That is not a cynical take. It is the position of every drug regulator that has looked at the question, and their standard of proof is worth borrowing.

What it takes to legally call two topical products equivalent

For an oral tablet, proving a generic matches the brand is comparatively easy: dose the drug, measure blood levels, compare curves. For a product that works locally on skin, blood levels are irrelevant, so the regulators had to find another route — and the route they mostly settled on is expensive.

A survey of fifteen international regulatory jurisdictions found that only four had specific guidance documents for topical products at all. Across all of them, the approaches consistently required were bioequivalence studies with clinical endpoints for most topical products, in vivo pharmacodynamic studies for corticosteroids specifically, and waivers only for simple solutions. A later critical appraisal of the European framework opens with the same observation: approval of topical generics is essentially governed by clinical endpoint studies, and the search for a cheaper surrogate is an active, unfinished research programme.

Read that again with a dupe video in mind. To claim two topical products are equivalent, a pharmaceutical company must generally run a clinical trial. The bar is that high specifically because everyone in the field knows the ingredient list cannot carry the claim. Waivers exist for solutions — the one dosage form where there is nothing to get wrong — which is a very precise hint about where genuine dupes live.

The experiment that should have settled this in 1987

There is an old, brutal piece of evidence for this, and it comes from the most controlled corner of topical medicine.

Researchers compared brand-name triamcinolone acetonide, fluocinolone acetonide and betamethasone valerate against their generic equivalents using the vasoconstrictor assay — a pharmacodynamic measure of how much the steroid actually blanches skin, which is a proxy for how much drug is reaching its target. Same steroid. Same concentration. Same nominal dosage form. Large differences were found between the generic and brand-name formulations, in both cream and ointment vehicles, with the authors concluding that clinically significant differences in therapeutic effectiveness should be expected.

That is prescription pharmaceuticals, under manufacturing controls that cosmetics never face, with an objectively measurable endpoint. If the ingredient list cannot guarantee equivalence there, the idea that it does so for an unregulated moisturiser is not a stretch — it is a category error. Vehicle is not packaging for the active. Vehicle is half the drug.

Four things a defensible dupe has to match

So what would a real one look like? Four criteria, and all four have to hold.

The same active, not a relative. Retinol and retinaldehyde are not interchangeable; ascorbic acid and its stabilised esters convert at different rates and to different extents; azelaic acid at a prescription strength in a gel is not the over-the-counter suspension in a different base. "Both have vitamin C" is where most comparisons quietly die.

The same concentration, disclosed. If one product discloses ten per cent and the other declines to say, that is not a match — it is one known quantity and one unknown. Our ingredient-decoder tool at least tells you where an ingredient sits in the list, which sets an upper bound when the brand will not.

A comparable vehicle. This is the criterion the genre ignores entirely, and it is the one the steroid data says matters most. An aqueous solution, an anhydrous silicone base and an oil-in-water emulsion deliver the same molecule at meaningfully different rates.

The same use conditions. Contact time, leave-on versus rinse-off, and pH where the active is pH-dependent. A salicylic acid cleanser and a salicylic acid leave-on are not versions of one another at any price, because the cleanser spends most of its life going down a drain.

Where dupes are real, and the price gap is indefensible

Now the good news, because dupes genuinely exist and they cluster somewhere predictable: single-active products with very few formulation degrees of freedom.

A plain ↗salicylic acid solution is the clearest case. Two per cent acid, an appropriate low pH, a solubiliser, water — there is not much room for one company to be cleverer than another, which is why something like ↗The Ordinary Salicylic Acid 2% Anhydrous Solution does the same job as products positioned several tiers above it. The same logic covers a straightforward ↗niacinamide serum such as ↗Good Molecules Niacinamide Serum, or a basic azelaic acid treatment. These are commodities in the economic sense: the raw material is cheap, the formulation is simple, and the premium is buying you a nicer bottle and a better-known name.

The honest position on that category is not "the expensive one is a scam." It is that the formulation contains little that could justify the multiple, and if the cheaper one feels acceptable on your skin, you are not compromising on anything measurable. Our dupe-finder tool is built to surface exactly these — matches on active, concentration and vehicle rather than on a shared word.

Where they mostly don't exist

Dupe logic fails most dangerously in sunscreen, because the failure is invisible.

Sun protection factor is a property of a specific finished formulation as tested, not of the filters inside it. Two products can carry the same filters at similar percentages and test differently, because film-forming polymers, emulsion stability and how evenly the product spreads all determine how much protection actually lands on skin. Worse, the filters interact chemically with each other. Work on filter-filter interactions found that pairing avobenzone with other UV filters can produce synergistic photostabilisation — or accelerated decomposition, if a photoreaction occurs between the components. A formula built around modern filters such as those in ↗RMK UV Face Protector SPF50+ is not reproducible by assembling a similar-looking filter list, because the combination and the base are the product.

Complex emulsions are the second category. Everything people actually like about a cream such as ↗Clinique Dramatically Different Moisturizing Lotion+ or ↗Kiehl's Creme de Corps — how it spreads, how quickly it disappears, whether it pills under sunscreen — comes from the emulsifier system, the rheology modifiers and the processing, none of which appear meaningfully in a dupe comparison. And occlusive classics like ↗Elizabeth Arden Eight Hour Cream are mostly petrolatum, which means the honest comparison is with plain petrolatum jelly rather than with another prestige balm — a genuine dupe, and a much less flattering one for the original than any competitor.

The third category is anything sold on texture, which is most of the enjoyable end of skincare. There is no ingredient-list route to "feels like this."

Reading a comparison honestly, including what you give up

A good dupe comparison names the trade, and there almost always is one. Packaging that excludes air and light matters enormously for ascorbic acid and retinaldehyde and not at all for glycerin. A fragranced version of a formula is not a dupe for a fragrance-free one if your skin reacts. A product that reformulates without announcing it is a moving target, which is why comparisons age badly and why the compare tool works from current data rather than from a screenshot someone took last year.

And sometimes the trade runs the other way. A cheaper product with a better-chosen vehicle can outperform the thing it was imitating, which the dupe framing cannot express at all, because it assumes the expensive one is the reference standard. It is a formulation, not a benchmark.

Here is where we land. Ask four questions of any dupe claim — same active, same concentration, comparable vehicle, same use conditions — and most of the genre evaporates. What survives is a real and useful list, concentrated in simple single-active products where the premium version is genuinely selling you very little. Buy those without guilt. For everything else, the cheap product is not a bargain version of the expensive one. It is a different product, which may be better or worse for you, and deserves to be judged on its own.